Organic Letters
Letter
Diederich, F. Org. Biomol. Chem. 2009, 7, 3947. (c) Persch, E.;
Dumele, O.; Diederich, F. Angew. Chem., Int. Ed. 2015, 54, 3290.
(d) Fah, C.; Hardegger, L. A.; Ebert, M.-O.; Schweizer, W. B.;
Diederich, F. Chem. Commun. 2010, 46, 67.
(5) (a) Peng, W.; Shreeve, J. M. J. Org. Chem. 2005, 70, 5760.
(b) Pravst, I.; Zupan, M.; Stavber, S. Synthesis 2005, 2005, 3140.
(c) Singh, R. P.; Majumder, U.; Shreeve, J. M. J. Org. Chem. 2001, 66,
6263.
(6) (a) Yang, M.-H.; Orsi, D. L.; Altman, R. A. Angew. Chem., Int. Ed.
2015, 54, 2361. (b) Ge, S.; Chaladaj, W.; Hartwig, J. F. J. Am. Chem.
Soc. 2014, 136, 4149. (c) Han, C.; Kim, E. H.; Colby, D. A. J. Am.
Chem. Soc. 2011, 133, 5802.
(7) (a) Shimada, Y.; Taniguchi, N.; Matsuhisa, A.; Sakamoto, K.;
Yatsu, T.; Tanaka, A. Chem. Pharm. Bull. 2000, 48, 1644. (b) Baudoux,
J.; Cahard, D. Org. React. 2007, 69, 347.
good yields, respectively, by using aqueous HBr and stirring at
room temperature for 4 h (Scheme 4).
In conclusion, we have successfully developed a simple and
efficient domino transformation of methylvinylketones to α,α-
difluorocyclopentanone derivatives using unique TMSCF2Br as
a difluorocarbene agent. A complete self-assistance strategy
based on TMSCF2Br enables the conversion to occur smoothly
under the catalysis of 5 mol % of TBAB via the in situ formation
of silyl dienol ethers, difluorocyclopropanation, thermal ring
opening and recyclization rearrangement, and desilylation. This
process represents the first example for the catalytic synthesis of
difluorinated cyclic compounds from fluorocarbon precursors.
The reliable installation of a difluoromethylene fragment at the
α-position of readily available ketones makes the method well-
suited for wide applications in organic synthesis and drug
design. Further work on the application and extension of the
scope of the protocol are currently under investigation in our
laboratory.
(8) Meegalla, S. K.; Doller, D.; Liu, R.; Sha, D.; Lee, Y.; Soll, R. M.;
Wisnewski, N.; Silver, G. M.; Dhanoa, D. Bioorg. Med. Chem. Lett.
2006, 16, 1702.
(9) Aono, T.; Sasagawa, H.; Fuchibe, K.; Ichikawa, J. Org. Lett. 2015,
17, 5736.
(10) (a) Hudlicky, T.; Kutchan, T. M.; Naqvi, S. M. Org. React. 1985,
́
ASSOCIATED CONTENT
* Supporting Information
The Supporting Information is available free of charge on the
33, 247. (b) Wong, H. N. C.; Hon, M. Y.; Tse, C. W.; Yip, Y. C.;
Tanko, J.; Hudlicky, T. Chem. Rev. 1989, 89, 165. (c) Baldwin, J. E.
Chem. Rev. 2003, 103, 1197.
(11) Orr, D.; Percy, J. M.; Tuttle, T.; Kennedy, A. R.; Harrison, Z. A.
Chem. - Eur. J. 2014, 20, 14305.
(12) (a) Liu, X.; Xu, C.; Wang, M.; Liu, Q. Chem. Rev. 2015, 115,
683. (b) Xu, C.; Liu, J.; Ming, W.; Liu, Y.; Liu, J.; Wang, M.; Liu, Q.
Chem. - Eur. J. 2013, 19, 9104. (c) Zheng, G.; Ma, X.; Li, J.; Zhu, D.;
Wang, M. J. Org. Chem. 2015, 80, 8910.
(13) (a) Song, X.; Chang, J.; Zhu, D.; Li, J.; Xu, C.; Liu, Q.; Wang, M.
Org. Lett. 2015, 17, 1712. (b) Chang, J.; Song, X.; Huang, W.; Zhu, D.;
Wang, M. Chem. Commun. 2015, 51, 15362. (c) Song, X.; Tian, S.;
Zhao, Z.; Zhu, D.; Wang, M. Org. Lett. 2016, 18, 3414.
(14) CCDC 1521772 contains the supplementary crystallographic
data for 2a for this paper. These data can be obtained free of charge
from The Cambridge Crystallographic Data Centre via www.ccdc.cam.
■
S
Experimental procedures, analytical data for new
Crystallographic data for 2a (CIF)
AUTHOR INFORMATION
Corresponding Authors
■
ORCID
(15) 2ac′ was formed by further difluorocyclopropanation, ring
opening, and defluorination of the acetyl group of 2ac.
(16) 2ac″ was formed by further difluorocyclopropanation, ring
opening, and protonation of the acetyl group of 2ac.
(17) Fuchibe, K.; Takayama, R.; Yokoyama, T.; Ichikawa, J. Chem. -
Eur. J. 2017, 23, 2831.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We thank the National Natural Sciences Foundation of China
(NNSFC-21372040 and 21672032) and the State Key
Laboratory of Fine Chemicals (KF1502) for funding support
of this research.
REFERENCES
■
(1) For reviews, see: (a) Trost, B. M. Science 1991, 254, 1471.
(b) Tietze, L. F. Chem. Rev. 1996, 96, 115. (c) Sheldon, R. A. Pure
Appl. Chem. 2000, 72, 1233. (d) Pellissier, H. Chem. Rev. 2013, 113,
442.
́ ̀
(2) (a) Inhibition of Enzymes by Fluorinated Compounds. Begue, J.-
P.; Bonnet-Delpon, D. Bioorganic and Medicinal Chemistry of Fluorine;
Wiley: Hoboken, NJ, 2008; Chapter 7, p 246. (b) Fluorine in
Medicinal Chemistry and Chemical Biology; Ojima, I., Ed.; Wiley: West
Sussex, 2009; p 29. (c) Fluorine in Medicinal Chemistry and Chemical
Biology; Ojima, I., Ed.; Wiley: Chichester, 2009.
(3) (a) Han, C.; Salyer, A. E.; Kim, E. H.; Jiang, X.; Jarrard, R. E.;
Powers, M. S.; Kirchhoff, A. M.; Salvador, T. K.; Chester, J. A.;
Hockerman, G. H.; Colby, D. A. J. Med. Chem. 2013, 56, 2456.
(b) Gelb, M. H.; Svaren, J. P.; Abeles, R. H. Biochemistry 1985, 24,
1813. (c) Takahashi, L. H.; Radhakrishnan, R.; Rosenfield, R. E.;
Meyer, E. F.; Trainor, D. A. J. Am. Chem. Soc. 1989, 111, 3368.
(4) (a) Dan, N.; Bhakat, S. Eur. J. Med. Chem. 2015, 95, 324. (b) Fah,
C.; Hardegger, L. A.; Baitsch, L.; Schweizer, W. B.; Meyer, S.; Bur, D.;
D
Org. Lett. XXXX, XXX, XXX−XXX